Amylin gets full value from $7bn BMS/AZ acquisition

Amylin appears to have realized full value for its Byetta/Bydureon franchise in diabetes through an acquisition by Bristol-Myers Squibb worth $31 per share, that will cost the pharma major some $7 billion, including the $1.7 billion in debt and obligations that Amylin holds. But what re-started the acquisition by BMS was the intervention by AstraZeneca to pay some $3.4 billion for certain rights to Amylin's portfolio and pipeline.

Amylin appears to have realized full value for its Byetta/Bydureon franchise in diabetes through an acquisition by Bristol-Myers Squibb worth $31 per share, that will cost the pharma major some $7 billion, including the $1.7 billion in debt and obligations that Amylin holds. But what re-started the acquisition by BMS was the intervention by AstraZeneca to pay some $3.4 billion for certain rights to Amylin's portfolio and pipeline.

More from Alimentary/Metabolic

More from Therapeutic Category

AbbVie On A STEAP Learning Curve In ADCs

 

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By 

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.